Impact of Inhaled Tranexamic Acid in Pulmonary Hemorrhage in Pediatric Intensive Care Unit

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07481682

Enrollment

100

Registered

2026-03-19

Start date

2023-08-01

Completion date

2024-09-01

Last updated

2026-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intensive Care Unit, Pediatric, Pulmonary Hemorrhage, Tranexamic Acid

Brief summary

This study aimed to detect the impact of inhaled Tranexamic acid® in pulmonary hemorrhage in pediatric intensive care unit.

Detailed description

Pulmonary hemorrhage, often manifested as hemoptysis, can be a severe and life-threatening condition. Tranexamic acid (TXA)® is a lysine analog that prevents the conversion of plasminogen to plasmin and inhibits plasmin's binding to fibrin, stabilizing the fibrin matrix and reducing bleeding.

Interventions

DRUGTranexamic acid + conventional therapy.

Patients received inhaled or endotracheally instilled Tranexamic acid (TXA) in addition to conventional therapy.

DRUGTranexamic acid

Patients received conventional systemic Tranexamic acid (TXA) alone.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

1 Months to 216 Months

Healthy volunteers

Inclusion criteria

* Age from 1 to 216 months. * Both sexes. * Patients with pulmonary hemorrhage.

Exclusion criteria

* Disseminated Intravascular Coagulation (DIC). * Laryngeal oedema. * Laryngeal web. * Contraindications to tranexamic acid include arterial thrombosis, pre-existing coagulopathy, or oral anticoagulant treatment. * Patients with traumatic lesions such as hemothorax.

Design outcomes

Primary

Measure	Time frame	Description
Cessation of pulmonary hemorrhage	48 hours of starting inhaled tranexamic acid	The cessation of pulmonary hemorrhage within 48 hours of starting inhaled tranexamic acid was recorded.
Incidence of adverse effects	48 hours of starting inhaled tranexamic acid	Incidence of adverse effects was recorded.

Secondary

Measure	Time frame	Description
In-hospital mortality	48 hours of starting inhaled tranexamic acid	Incidence of in-hospital mortality was recorded.
Length of hospital stay	Till the discharge from the hospital (Up to 2 weeks)	Length of hospital stay was recorded from the admission till the discharge from the hospital.

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 20, 2026